EQT Life Sciences-Backed AgomAb Falls After $200 Million IPO

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company backed by EQT Life Sciences, closed 8.4% below its IPO price in its trading debut Friday after the firm raised $200 million in a listing.

Its American depositary receipts closed at $14.65 each in New York, versus an initial public offering price of $16. The company sold 12.5 million ADRs on Thursday, after marketing them for $15 to $17 apiece. Each ADR represents one ordinary share, according to its regulatory filings.